4Tissue
ActiveSummary
The annual accounts of 4Tissue for fiscal year 2025 show a net loss of 127% of the equity at the start of that year. The 2025 annual accounts show equity of €845,476 and a net result of -€727,036. Equity is growing by ~74.3% per year across the filed fiscal years. Its solvency ranks better than 43% of 651 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 1.1% (low).
Checked score
Score 2025
59
/ 100
Fair
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability50▲+50
Solvency58▼-3
Growth52=
Track record94
Bankruptcy probability, 12 months
1.1%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €45,000 at 30 days only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 10.66 against 33.01 in 2024; short-term debt: 7% and cash: 4.8% of total assets), but 67% of the assets are financed with debt.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Three signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 32
Relative position
BE, all sectors
reference
Other manufacturing (NACE 32)
about 28% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-06-2026, 50 days ahead of the deadline.
NBB · 3 filingsDeviation from the deadline
2025
50 d early
2024
38 d early
2023
51 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 3 accounts on average 12 days before the deadline; the sector median for financial year 2024 is 2 days before the deadline, and 40% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
26-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file What other support did companies like this one receive, and it did not?Subsidy mirror How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, micro schema
Equity
€845,476▲ 47.6%
2024 · €572,712
Total assets
€2.6m▲ 59.5%
2024 · €1.6m
Net result
-€727,036▼ 126%
2024 · -€321,213
Working capital
€1.7m▲ 20.7%
2024 · €1.4m
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line202320242025
Operating result-€21,045--€334,746▼ 1,491%-€771,968▼ 131%
Net result-€21,074--€321,213▼ 1,424%-€727,036▼ 126%
Equity-€6,074-€572,712€845,476▲ 47.6%
Total assets€6,325-€1.6m▲ 25,268%€2.6m▲ 59.5%
Debt€12,399-€1.0m▲ 8,222%€1.7m▲ 66.1%
Working capital-€6,074-€1.4m€1.7m▲ 20.7%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €771,968 in 2025 against €334,746 in 2024; the loss grows and 2025 has the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €2.6m
Fixed assets
€650,355 ▲ 413%
Current assets
€1.9m ▲ 29.2%
Equity and liabilities €2.6m
Equity
€845,476 ▲ 47.6%
Debt
€1.7m ▲ 66.1%
Debt's share of the balance-sheet total rises from 64.3% to 67.0%. Equity and debt are higher.
Key figures and ratios
EBITDA
€17,485▲
2024 · -€146,215
Cash flow
€62,416▲
2024 · -€132,683
Current ratio
10.66▼
2024 · 33.01
Debt to equity
2.03▲
2024 · 1.80
ROE
-86.0%▼
2024 · -56.1%
ROA
-28.4%▼
2024 · -20.0%
Interest coverage
22.27▲
2024 · -3361.26
Debt ≤ 1 year
€179,111▲
2024 · €44,764
Income taxes
-€40,121▼
2024 · -€12,113
Staff costs
€309,690▲
2024 · €31,834
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | €31,834 | €309,690 | ▲ 873% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | €188,531 | €789,452 | ▲ 319% |
| Other operating charges640/8 | - | €899 | €578 | ▼ 35.7% |
| Gross operating margin9900 | -€21,045 | -€113,482 | €327,753 | ▲ 389% |
| Operating profit (loss)9901 | -€21,045 | -€334,746 | -€771,968 | ▼ 131% |
| Financial income75/76B | - | €1,463 | €5,596 | ▲ 282% |
| Recurring financial income75 | - | €1,463 | €5,596 | ▲ 282% |
| Financial charges65/66B | €29 | €44 | €785 | ▲ 1,705% |
| Recurring financial charges65 | €29 | €44 | €785 | ▲ 1,705% |
| Profit (loss) for the period before taxes9903 | -€21,074 | -€333,326 | -€767,157 | ▼ 130% |
| Income taxes67/77 | - | -€12,113 | -€40,121 | ▼ 231% |
| Profit (loss) for the period9904 | -€21,074 | -€321,213 | -€727,036 | ▼ 126% |
| Profit (loss) for the period to be appropriated9905 | -€21,074 | -€321,213 | -€727,036 | ▼ 126% |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Assets | ||||
| Total assets20/58 | €6,325 | €1.6m | €2.6m | ▲ 59.5% |
| Fixed assets21/28 | - | €126,803 | €650,355 | ▲ 413% |
| Intangible fixed assets21 | - | €126,803 | €583,774 | ▲ 360% |
| Tangible fixed assets22/27 | - | - | €66,581 | - |
| Plant, machinery and equipment23 | - | - | €66,581 | - |
| Current assets29/58 | €6,325 | €1.5m | €1.9m | ▲ 29.2% |
| Amounts receivable after more than one year29 | - | €455,450 | €691,224 | ▲ 51.8% |
| Other amounts receivable291 | - | €455,450 | €691,224 | ▲ 51.8% |
| Amounts receivable within one year40/41 | €2,385 | €248,624 | €731,744 | ▲ 194% |
| Other amounts receivable41 | €2,385 | €248,624 | €731,744 | ▲ 194% |
| Current investments50/53 | - | - | €355,222 | - |
| Cash at bank and in hand54/58 | €3,940 | €771,689 | €122,182 | ▼ 84.2% |
| Deferred charges and accrued income490/1 | - | €1,999 | €8,543 | ▲ 327% |
| Equity and liabilities | ||||
| Total equity and liabilities10/49 | €6,325 | €1.6m | €2.6m | ▲ 59.5% |
| Equity10/15 | -€6,074 | €572,712 | €845,476 | ▲ 47.6% |
| Contributions10/11 | €15,000 | €915,000 | €1.9m | ▲ 109% |
| Profit (loss) carried forward14 | -€21,074 | -€342,288 | -€1.1m | ▼ 212% |
| Amounts payable17/49 | €12,399 | €1.0m | €1.7m | ▲ 66.1% |
| Amounts payable within one year42/48 | €12,399 | €44,764 | €179,111 | ▲ 300% |
| Trade debts44 | €12,399 | €40,865 | €140,970 | ▲ 245% |
| Suppliers440/4 | €12,399 | €40,865 | €140,970 | ▲ 245% |
| Taxes, remuneration and social security45 | - | €3,561 | €37,804 | ▲ 962% |
| Remuneration and social security454/9 | - | €3,561 | €37,804 | ▲ 962% |
| Other amounts payable47/48 | - | €337 | €337 | = |
| Accrued charges and deferred income492/3 | - | €987,090 | €1.5m | ▲ 55.5% |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Profit (loss) for the period9904 | -€21,074 | -€321,213 | -€727,036 | ▼ 126% |
| + Depreciation and write-downs630 | - | €188,531 | €789,452 | ▲ 319% |
| Operating cash flow (approximation) | -€21,074 | -€132,683 | €62,416 | ▲ 147% |
| Investment in fixed assets (approximation) | - | - | -€1.3m | - |
| Change in cash | - | €767,749 | -€649,507 | ▼ 185% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
23-09
State Gazette act
Resignations: Benoit MOREAUX (ceo) and ROBIUM (ceo / coo)Permanent representatives: MOREAUX Benoit Christian Jean-Claude, An VAN DEN BULCKE and Stephanie DUPONT · Appointment: Maracujas BV (ceo/algemeen directeur)7 facts ▸
State Gazette act
Resignations: Benoit MOREAUX (ceo) and ROBIUM (ceo / coo)
Permanent representatives: MOREAUX Benoit Christian Jean-Claude, An VAN DEN BULCKE and Stephanie DUPONT · Appointment: Maracujas BV (ceo/algemeen directeur)7 facts ▸
- Board meeting, 27-05-2026
- Director resignation, Benoit MOREAUX (ceo (persoon belast met dagelijks bestuur))
- Permanent representative, MOREAUX Benoit Christian Jean-Claude (permanent representative)
- Director resignation, ROBIUM ((interim) ceo / coo (persoon belast met dagelijks bestuur))
- Permanent representative, An VAN DEN BULCKE (permanent representative)
- Director appointment, Maracujas BV (ceo/algemeen directeur)
- Permanent representative, Stephanie DUPONT (permanent representative)
11-06
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Weakest financial yearnet -€727,036
Net result drops to -€727,036, the lowest in the series.
23-06
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Liquidity times 65current ratio 33.01
Current ratio from 0.51 to 33.01.
31-12
Financial
Equity above €500,000Eq €572,712
Equity rises from -€6,074 to €572,712.
20-09
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 51 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 5 acts read
About the unread acts
Of the 5 Belgian State Gazette acts we know for this company, 1 has been read. The other 4 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
1 office holder, last change in 2026
Day-to-day management 1
MARACUJAS
CurrentCeo/algemeen directeur · since 27-04-2026 · Private limited company · perm. rep.: Stephanie DUPONT
Permanent representatives 1
Stephanie DUPONT
CurrentPermanent representative · since 27-04-2026 · for MARACUJAS
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
4 of this company's 5 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Gent · 1 establishment unit since 2023
Ground area
9,157 m²
Building footprint
2,487 m²
Volume, LiDAR
31,072 m³
Parcel 44082B0134/00G000, Flanders · tallest building 20.2 m, ±3 floors. Linked by address, not a title deed.
12
companies at this address
See who is registered here
1 establishment unit
4Tissue
since 20232.342.990.557
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44082B0134/00G000 | Flanders | 9,157 m² | 1 · 2,487 m² | 20.2 m · 3 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
3 people since 2025, 1 in office
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| MARACUJAS |
|
| ROBIUM |
|
| BENOIT MOREAUX |
|
Articles of association
Other provisions
Emmanuel Casier
VVGB Advocaten-Avocats
PKF Bofidi Accountants & Advisers BV
Lindsey Schamp
Ellen Carlier
Lisa Kennis
Sylvia Vanbeveren
Suzana Fernandes
Kim Forment
Tine Talpe
Jeroen Vandewalle
Structure & network
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Public money · subsidies and aid
Flemish government
2024 to 2025 · 5 entries · 1,213,477 EUR awarded · 489,600 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 3 | 898,676 EUR | 364,000 EUR |
| 2024 | 2 | 314,801 EUR | 125,600 EUR |
European Union, budget
2024 to 2025 · 4 entries · 1,109,009 EUR in total| Year | Entries | awarded |
|---|---|---|
| 2025 | 2 | 375,200 EUR |
| 2024 | 2 | 733,809 EUR |
Projects
STRONG-UR - STRATEGIES FOR OPTIMISED BIOPRINTING OF NEXT GENERATION TISSUES FOR URETHRAL REGENERATION AND TRANSLATION (STRONG-UR)
ADVANCED 4D BIOMATERIALS FOR MUCOSA AND SUB-MUCOSA TREATMENT IN PATIENTS AFFECTED BY INTESTINAL DISEASES
European research
2 projects · 1,109,013 EUR EU contributionProgrammes
Projects
STRategies for Optimised bioprinting of Next Generation tissues for URethral regeneration and translation (STRONG-UR)
ADvAnced 4D biomAteriaLs for mucosa and sub-mUcosa treatment in patients affected by intestinal diSeases
Similar companies · same sector, comparable size
GERAERTS ORTHOPEDIE
BE 0808.412.054
Lommel · Eq €854,402
ORTHOPEDICO
BE 0822.077.176
Geel · Eq €828,028
QUALITY PRODUCTION
BE 0430.629.025
Genk · Eq €868,250
Eqwal Braine-l’Alleud
BE 0893.119.481
Braine-l'Alleud · Eq €819,842
Guy Adriaens Dental Labo
BE 0821.306.225
Mol · Eq €819,127
Of 1,248 companies in sector 32500 we hold annual accounts for 694. 451 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded17-03-2023
Fiscal year end31-12
Activities, NACEBEL 2025
32500Manufacture of medical and dental instruments and supplies
74999Other professional, scientific and technical activities
Scores and ratios are computed by Checked and are not a credit decision.